Research·October 23, 2026 at 10:33 AM EDT·3 sources
Bristol Myers reveals autoimmune CAR-T trial death, explains summertime pause
BMY -2.4%NVS
BMY · last 30 trading days+0.6% since the news
News
What happened
- A patient died in a Bristol Myers Squibb study of autoimmune CAR-T, a technology whose development was questioned after Bristol Myers and Novartis paused similar programs this summer. [1]
Why it matters
The death and program pause may affect clinical-development plans and investor assessments of autoimmune CAR-T therapies.
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- EarlierOct 23Novartis’ Kisqali Cuts Death Risk 19% in Breast Cancer Study
- First reported by Endpoints NewsOct 23Bristol Myers reveals autoimmune CAR-T trial death, explains summertime pause
- Bloomberg reportsOct 23Bristol Myers Reports CAR-T Death as Safety Concerns Mount
- STAT reportsOct 23STAT+: Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
Who is involved
Bristol Myers reveals autoimmune CAR-T trial death, explains …Bristol Myers SquibbBMYNovartisNVS
Company
Sources (3)
Related
- 4h · #ESMO26: Roche details magnitude of its KRAS G12C inhibitor’s win over rivals in lung cancer trial
- 4h · Roche Drug Outshines Amgen, Bristol Rivals in Lung Cancer Study
- 9h · #ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activity
- Oct 23 · Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials
- Oct 23 · Novartis Multiple Sclerosis Pill Missed Expectations in Key Study
- Oct 23 · Novartis’ Kisqali Cuts Death Risk 19% in Breast Cancer Study
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.